leadf
logo-loader
viewVentriPoint Diagnostics Ltd.

VentriPoint rises as it announces prototype of VMS-plus 3.0

Ventripoint's technology is a leading artificial intelligence approach known as knowledge-based reconstruction, used to create applications to monitor heart disease

Heart - biology
Heart disease is a leading cause of death

VentriPoint Diagnostics Ltd (CVE:VPT) has built a prototype of an improved version of its VMS-plus heart analysis system.

This new device, designated VMS-plus 3.0, is undergoing final testing and development to verify its performance.

READ: VentriPoint Diagnostics shares up as it files patent for new invention

The new design eliminates the need for patients to remain motionless during image acquisition and improves the work-flow of the VMS-plus through a more intuitive user interface, Ventripoint said.

The new device will reduce the cost of its equipment significantly and allow a “per-use” sales model that is expected to prove especially appealing to small and medium-sized medical centres.

The company intends to offer both a capital purchase as well as the subscription option to customers starting in 2019.

Shares in VentriPoint were up 4.4% at C$0.24.

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.075 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $5.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Ventripoint Diagnostic focussing on sales in 2020 as they...

Ventripoint Diagnostics (CVE:VPT-OTCQB: VPTDF) Executive Chairman and Acting CEO Dr George Adams sat down with Steve Darling from Proactive in Vancouver with news the company has 11 purchase orders in for their echocardiogram system that provides cardiac measurements. Adams telling Proactive...

on 20/2/20

2 min read